Oral NSAIDs promising on paper, but CF clinicians wary

The release of a Cochrane review showing high dose oral NSAIDs can slow the progression of lung damage in people with cystic fibrosis is unlikely to change clinical practice, says a leading Australian respiratory physician and researcher. Associate Professor Sarath Ranganathan, director of Respiratory and Sleep Medicine at the Royal Children’s Hospital in Melbourne, and ...